यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabas - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatito veikėjai, išskyrus kortikosteroidus - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

schulke & mayr gmbh - oktenidinas/fenoksietanolis - odos purškalas (tirpalas) - 1 mg/20 mg/ml - octenidine, combinations

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - poli(0-2-hidroksietil) krakmolas/natrio chloridas/kalio chloridas/kalcio chloridas dihidratas/magnio chloridas heksahidratas/natrio acetatas trihidratas/obuolių rūgštis - infuzinis tirpalas - 60 g/6,25 g/0,3 g/0,37 g/0,2 g/3,27 g/0,67 g/1000 ml - hydroxyethylstarch

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - metildopa - tabletės - 250 mg - methyldopa (levorotatory)

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

norameda, uab - furozemidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - furosemide

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - linkomicinas - injekcinis ar infuzinis tirpalas - 500 mg; 300 mg/ml - lincomycin

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - sufentanilis - injekcinis ar infuzinis tirpalas - 5 µg/ml - sufentanil

लिथुआनिया - लिथुआनियाई - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - sufentanilis - injekcinis ar infuzinis tirpalas - 50 µg/ml - sufentanil

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirusiniai vaistai sisteminiam naudojimui - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.